Hidehito Horinouchi, Assistant Chief at National Cancer Center Hospital, shared an article Fabian J. Bolte and his colleagues authored on X:
“Real-World Outcomes of Tarlatamab in SCLC.
Special considerations are required for patients with brain metastasis due to the increased risk of severe.
Dr. Fabian J. Bolte.”
Authors: Fabian J. Bolte et al.
Further Reading: